- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- ALPA LAB
ALPA LAB Share Price 
(ALPA)
Here is the latest stock price and chart of ALPA LAB. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Sep 25, 2018 12:23:00 PM | ||
|---|---|---|---|
| Price (Rs)29.35 | Open (Rs) 29.05 | High (Rs) 29.70 | Low (Rs) 29.05 |
| % Change0.34 | Volume 2,652 | Value (Rs) 77,836 | 52-Week H/L 56.60 / 24.00 |
| Live NSE Quotes | Sep 25, 2018 12:24:11 PM | ||
|---|---|---|---|
| Price (Rs)29.15 | Open (Rs) 30.00 | High (Rs) 30.95 | Low (Rs) 29.00 |
| % Change-1.69 | Volume 10,035 | Value (Rs) 297,337 | 52-Week H/L 56.45 / 23.35 |
| BSE Sensex | CNX Nifty |
- Charts
-
PERIOD - Advanced Charts new
- Charts by TradingView
ALPA LAB Share Price Today:
ALPA LAB share price is up 0.3% to Rs 29.4 on the BSE. On the NSE, the ALPA LAB share price is down 1.7% to Rs 29.2. The total volume of shares traded is 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading up by 1.3%. And the benchmark S&P BSE SENSEX is at 36,426.1 (up 0.3%).
Over the last 30 days, the ALPA LAB share price is down 7.1%. And over the last one year, ALPA LAB share price is down 3.1%.
|
| |
Today's Market
Sensex Opens Flat; Realty & Bank Stocks Lose(09:30 am)
Asian stock markets opened in red today after a new round of US-China trade tariffs kicked in. Meanwhile, the S&P 500 and the Dow closed lower on Monday as market participants awaited.
Related Views On News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
Laurus Labs Ltd (IPO)
Dec 6, 2016Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.
More Views on NewsMost Popular
My First Pharma Stock Recommendation!(The 5 Minute Wrapup)
Sep 21, 2018This company has not only created a niche in the pharma space, it has done so profitably.
Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)
Sep 12, 2018Richa has discovered the single most profitable opportunity in the market - read on to discover more...
Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)
Sep 12, 2018PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.
Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)
Sep 14, 2018Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.
How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)
Sep 17, 2018PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.
MoreTRACK ALPA LAB
- Track your investment in ALPA LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.